A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of Ridinalazole for 10 days with Vancomycin for 10 days in the treatment of Clostridium difficile (C Diff) Infectionmidwayadmin2019-04-24T18:12:28+00:00
A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of Ridinalazole for 10 days with Vancomycin for 10 days in the treatment of Clostridium difficile (C Diff) Infection
SMT19969/C004 · Trial ·
Major Inclusion/Exclusion Criteria
-
Have signs and symptoms associated with CDI including >3 unformed bowel movements in the last 24 hours
-
Have not had more than one prior episode of CDI in the previous 3 months or more than 3 episodes in the past 12 months
-
Have had no more than 24 hours of treatment with antimicrobial treatment active against CDI
-
Does not have a diagnosis of inflammatory bowel disease (current or historical)